M&A Deal Summary |
|
|---|---|
| Date | 2020-09-08 |
| Target | Aspen Pharmacare Holdings - Thrombosis Business |
| Sector | Life Science |
| Buyer(s) | Viatris |
| Sellers(s) | Aspen Pharmacare |
| Deal Type | Divestiture |
| Deal Value | 642M EUR |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1961 |
| Sector | Life Science |
| Employees | 33,000 |
| Revenue | 15.4B USD (2023) |
Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 13 of 13 |
| Sector (Life Science) | 10 of 10 |
| Type (Divestiture) | 6 of 6 |
| Country (United Kingdom) | 1 of 1 |
| Year (2020) | 1 of 1 |
| Size (of disclosed) | 7 of 8 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-07-29 |
The Upjohn Company
Kalamazoo, Michigan, United States Upjohn seeks to leverage our portfolio, global experience and expertise to become the trusted partner of choice for all stakeholders committed to improving patient health. Upjohn focuses on relieving the burden of non-communicable diseases with trusted, quality medicines for every patient, everywhere. Upjohn brings together 20 of the industry's most trusted brands — products such as Lipitor, Norvasc, Lyrica and Viagra — with world-class medical, manufacturing and commercial expertise in more than 120 countries. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-02-28 |
Viatris - Biosimilars
Canonsburg, Pennsylvania, United States Viatris' Biosimilars provides affordable access to patients through its portfolio in diabetes, oncology, immunology, and other non-communicable diseases. Viatris' Biosimilars is based in Canonsburg, Pennsylvania. |
Sell | $3.3B |
| Category | Company |
|---|---|
| Founded | 1850 |
| Sector | Life Science |
| Employees | 8,612 |
| Revenue | 40.7B ZAR (2023) |
Aspen Pharmacare is a provider of specialty, branded, and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential. Aspen Pharmacare was founded in 1850 and is based in Durban, South Africa.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 2 |
| Country (United Kingdom) | 1 of 1 |
| Year (2020) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-10-31 |
New Zealand New Milk
Auckland, New Zealand New Zealand New Milk Ltd. is a producer of infant milk formula in Auckland, New Zealand. NZNM is one of a limited number of companies which holds the required endorsements from the Chinese regulatory authorities to produce infant milk formula for this key territory and the investment in NZNM represents another step towards Aspen’s aspirations to enter the Chinese infant milk formula sector, |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-03-01 |
Aspen Pharmacare Holdings - Prescription Medicines
Durban, South Africa Aspen brands portfolio includes the Trustan, Altosec, Zuvamor, Ciavor, Grantryl, and Aspen Granisetron brands. |
Sell | €105M |
